SAFETY AND  EFFICACY  OF TWO TACROLIMUS FORMULATIONS (PROGRAF® AND ADVAGRAF®) IN MALAYSIAN RENAL TRANSPLANT PATIENTS: A COMPARATIVE STUDY

Author: Mac Guad R ¹ ; Zaharan NL ² ; Wan Md Adnan WAH ³ ; Gan SH ⁴
Author Information

1. Department of Biomedical Science and Therapeutics, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia
2. Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
3. Division of Nephrology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur,, Malaysia
4. School of Pharmacy, Monash University Malaysia, Selangor Darul Ehsan, Malaysia
Publication Type:Journal Article
Keywords: Prograf®; Renal Transplant, Advagraf®; Acute Rejection, Safety
From:Journal of University of Malaya Medical Centre 2019;22(1):20-26
CountryMalaysia
Language:English
Abstract: A once-daily formulation of tacrolimus, Advagraf®, is increasingly being used in place of twice-daily tacrolimus, Prograf®, as a standard immunosuppressive agent for transplant patients. In this study, the clinical safety and efficacy of Advagraf® were compared with Prograf®, among multi-ethnic Malaysian renal transplanted population.
Full text:10.2013my0159.pdf